Business Summary

Amarin is a biopharmaceutical company. The Company is focused on the commercialization and development of therapeutics for cardiovascular health. The Company's main product, Vascepaź (icosapent ethyl) capsules, is for use as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. The Company refers this indication for Vascepa as the MARINE indication. Vascepa is available in the U.S. by prescription only. The Company is also developing Vascepa for the treatment of patients with high triglyceride levels who are also on statin therapy for elevated low-density lipoprotein cholesterol, levels which the Company refer to as mixed dyslipidemia.

Data provided by Mergent, Inc.

Recent Company News MORE »

Powered by Interactive Data Managed Solutions

Capital Raising Events MORE »

DR Price Date DR Price USD US / Non-US / Total DRs US / Non-US / Total DR Capital Raised USD
Jul 12, 2013 5.60 21,700,000
0
21,700,000
121,520,000
0
121,520,000
Jan 06, 2011 7.60 13,800,000
0
13,800,000
104,880,000
0
104,880,000
DR Symbol AMRN
CUSIP 023111206
DR Exchange NASDAQ Stock Market
DR ISIN US0231112063
Ratio DR:ORD 1:1
Depositary CIT (Sponsored)
Effective Date Apr 08, 1993
Country United Kingdom
Industry Pharma. & Biotech.

Powered by Interactive Data Managed Solutions

Monthly DR Trading Summary MORE »

Month Month End
DR Close
Price
DR Trading Volume Avg Day DR
Trading
Volume
Sep. 14 1.09 78,635,614 3,744,553
Aug. 14 1.93 53,438,513 2,544,691
Jul. 14 1.80 44,593,908 2,026,996
Data provided by Interactive Data Corp.

This information and data is provided for general informational purposes only. The Bank of New York Mellon and our information suppliers do not warrant or guarantee the accuracy, timeliness or completeness of this information or data. We provide no advice nor recommendation or endorsement with respect to any company or securities. We do not undertake any obligation to update or amend this information or data. Nothing herein shall be deemed to constitute an offer to sell or a solicitation of an offer to buy securities.
Please refer to
"Terms Of Use".

DEPOSITARY RECEIPTS:
NOT FDIC, STATE OR FEDERAL AGENCY INSURED
MAY LOSE VALUE
NO BANK, STATE OR FEDERAL AGENCY GUARANTEE
Data provided by Thomson Reuters, Inc.

© 2014 The Bank of New York Mellon Corporation. Depositary Receipt business and services are conducted through The Bank of New York Mellon.

Quotes delayed at least 15 minutes.Market data provided by Interactive Data
Terms & Conditions. Powered and implemented by Interactive Data Managed Solutions.

Certain information included in this website is proprietary to Mergent, Inc. (Mergent) Copyright © 2003-2010. Reproduction of such information in any form is prohibited. Because of the possibility of
human or mechanical error by Mergent's sources, Mergent or others, Mergent does not guarantee the accuracy, adequacy, completeness, timeliness or availability or for the results obtained from the
use of such information. Mergent Terms of Use apply

Holdings information provided by FactSet Research Systems Inc. Copyright © 2003-2014 FactSet Research Systems Inc. All rights reserved.

Thomson Reuters Marks: The THOMSON REUTERS Kinesis Logo depicted below and THOMSON REUTERS

Redistributor shall display or print the Thomson Reuters Trademarks when Redistributor’s Customers are given access to the Services.

Where Redistributor makes available on display any and all Thomson Reuters Marks attributable to the Services, Redistributor shall include the following language in the Help About
section or in a general attribution page: “The THOMSON REUTERS Kinesis Logo and THOMSON REUTERS are trademarks of Thomson Reuters and its affiliated companies in the
United States and other countries and used herein under license.”

Additional Attribution Guidelines by Thomson Reuters: Redistributor shall display or print the following notice in the Help About section or in a general attribution page. “Copyright ©,
Thomson Reuters, 1999-2014. All Rights Reserved. Use, duplication, or sale of this service, or data contained herein, except as described in the [Authorized Products name]
Subscription Agreement, is strictly prohibited.”